Relative efficacy of buprenorphine, nalbuphine and morphine in opioid-treated rhesus monkeys discriminating naltrexone

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1167-1173

  Sell, Stacy L ^a,c   McMahon, Lance R ^a   France, Charles P ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; LEVACETYLMETHADOL; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALBUPHINE; NALTREXONE; OPIATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; MALE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL;

ANIMALS; BUPRENORPHINE; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; FEMALE; MACACA MULATTA; MALE; METHADYL ACETATE; MORPHINE; NALBUPHINE; NALTREXONE; NARCOTICS; RECEPTORS, OPIOID, MU;

EID: 0041932084     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.051425     Document Type: Article

References (28)

1. A-ergic ligands. Psychopharmacology 153:67-84.
2. Brandt MR, Cabansag SR, and France CP (1997) Discriminative stimulus effects of L-a-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 282:574-584.
3. Brandt MR and France CP (1998) Chronic L-alpha acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal. J Pharmacol Exp Ther 287:1029-1037.
4. Comer SD and Collins ED (2002) Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 303:695-703.
5. De Souza EB, Schmidt WK, and Kuhar MJ (1988) Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther 244:391-402.
6. Dole VP and Nyswander MA (1965) A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. J Am Med Assoc 193:80-84.
7. Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, and Stitzer ML (1996) Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther 276:449-459.
8. France CP and Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937-943.
9. Gauthier CA and France CP (1999) The discriminative stimulus effects of naloxone and naltrexone in morphine-treated rhesus monkeys: comparison of oral and subcutaneous administration. Psychopharmacology 144:131-136.
10. Gerak LR, Butelman ER, Woods JH, and France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271:993-999.
11. Greenwald MK, Schuh KJ, Hopper JA, Schuster CR, and Johanson CE (2002) Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology 160:344-352.
12. Houtsmuller EJ, Walsh SL, Schuh KJ, Johnson RE, Stitzer ML, and Bigelow GE (1998) Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance. J Pharmacol Exp Ther 285:387-396.
13. Koek W (1999) N-Methyl-D-aspartate antagonists and drug discrimination. Pharmacol Biochem Behav 64:275-281.
14. Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186-216.
15. Liguori A, Morse WH, and Bergman J (1996) Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277:462-472.
16. Mhatre MC and Gonzalez LP (1999) Increased Ro15-4513-induced seizures following multiple ethanol withdrawals. Pharmacol Biochem Behav 63:93-99.
17. Morgan D and Picker MJ (1998) The mu opioid irreversible antagonist β-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the μ opioid receptor. Psychopharmacology 140:20-28.
18. Richards ML and Sadee W (1985) In vivo opiate receptor binding of oripavines to μ, δ and κ sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 114:343-353.
19. Schuster CR, Greenwald MK, Johanson C-E, and Heishman SJ (1995) Measurement of drug craving during naloxone-precipitated withdrawal in methadone-maintained volunteers. Exp Clin Psychopharmacol 3:424-431.
20. Sell SL and France CP (2002) Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys. J Pharmacol Exp Ther 301:1103-1110.
21. Strain EC, Walsh SL, and Bigelow GE (2002) Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology 159:161-166.
22. 2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats. J Pharmacol Exp Ther 271:959-968.
23. Walker EA and Young AM (2002) Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine. J Pharmacol Exp Ther 302:101-110.
24. Walker EA, Zernig G, and Woods JH (1995) Buprenorphine antagonism of μ opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273: 1345-1352.
25. Winger G and Woods JH (2001) The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. Drug Alcohol Depend 62:181-189.
26. Woods JH and Gmerek DE (1985) Substitution and primary dependence studies in animals. Drug Alcohol Depend 14:233-247.
27. Young AM, Kapitsopoulos G, and Makhay MM (1991) Tolerance to morphine-like stimulus effects of mu opioid agonists. J Pharmacol Exp Ther 257:795-805.
28. Zimmerman DM, Leander JD, Reel JK, and Hynes MD (1987) Use of β-funaltrexamine to determine μ opioid receptor involvement in the analgesic activity of various opioid ligands. J Pharmacol Exp Ther 241:374-378.